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Background. Urea pharmacokinetic equation systems have
contributed to better understanding of treatment dose among
hemodialysis patients. The methods are indirect, however, and
require the measurement of blood urea nitrogen (BUN) con-
centration before and after a dialysis session to estimate the
total treatment dose that clinicians prescribe [urea clearance
× dialysis time (Kt)] indexed to an estimate of body size [the
volume of urea distribution in the body (V)] yielding the ra-
tio, Kt/V. New technology permits direct on-line measurement
of average small molecule clearance (Kecn) during each dialy-
sis treatment that can be multiplied by time (t) to give a direct
measurement of total treatment dose (Kt). This study evaluated
the relationship of measured Kt with death risk. It also evalu-
ated the relationship of simple body size measures to risk and
also the combination of one such measure [body surface area
(BSA)] with Kt to death risk.
Methods. The data were taken from the Fresenius Medical
Care (NA) (FMCNA) clinical database that included patients
who had outcome data, height and weight measurements, and at
least one average Kecn and t measurement during April 2002.
Kecn, t, and the body size measures [body weight, body mass in-
dex (BMI), and BSA)] were averaged during the month. Those
values were used as predictors of survival during the next 1 year
in unadjusted and case mix adjusted proportional hazards (Cox)
models.
Results. Increasing values of Kecn, t, Kt and all of the body
size measures were associated with lower death risk. The body
size measure most closely associated with risk was the BSA that
was used in subsequent models. Kt and BSA were independent
risk predictors. There was a significant interaction between Kt
and BSA in the case mix but not the unadjusted model indicating
that the risk burden of lower total dialysis dose, Kt, may be
greater among small than large patients.
Conclusion. The direct measurement of dialysis dose during
each treatment is practical and the values reported by it are clin-
ically relevant. Higher dose was associated with better survival
in both small and large patients treated three times weekly. Fur-
thermore, smaller patients may require proportionately greater
total dose than larger patients to achieve comparable survival.
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Hemodialysis dose is often judged by indexing the to-
tal dose per treatment, taken as the product of dialyzer
small molecule (urea) clearance (Ku) and the length of
the treatment [time (t)], to an estimate of body size taken
as the volume of urea distribution in the body (V) yielding
the ratio, Kt/V [1]. The formulation arose from mathe-
matical models of urea kinetics during a dialysis cycle [2]
and has contributed to better understanding of dialysis
dosing methods that may have resulted in lower mortal-
ity among patients [3]. The actual, or physical, Ku and
V are not measured directly to produce the ratio Kt/V.
Two government-sponsored studies have used the kinetic
method either to control urea removal [National Coop-
erative Dialysis Study (NCDS)] [4] or to directly judge
the amount of treatment given patients [Hemodialysis
(HEMO)] Study [5]. Algebraic approximations are often
used to estimate a Kt/V [1, 6–8]. A simple but related
quantity, the urea reduction ratio (URR), is also com-
monly used to evaluate treatment [9, 10].
None of those methods directly measure the total dose
parameter, Kt, or the body size parameter, V. Estimating
dialysis dose has thus been limited to indirect methods re-
quiring calculation of a Kt/V from pre- and postdialysis
concentrations of blood urea nitrogen (BUN) because di-
rect on-line measurement of small molecule clearance has
been impractical. The frequency of clinical dose estimates
therefore has generally been limited to once monthly as a
practical necessity. Technologies have recently been de-
veloped, however, whereby a clearance [average small
molecule clearance (Kecn)] similar to urea clearance can
be measured directly during the course of each treatment
[11–14], called an on-line clearance. Average Kecn can be
multiplied by t to produce the total dose parameter, Kt,
at the end of treatment or even as a running value during
the course of treatment. Kt can then be indexed to an es-
timate of V, total body water (TBW), or any convenient
body size measure like body weight, body surface area
(BSA) or the body mass index (BMI).
One technology supporting the on-line measurement
of Kecn uses changes in transmembrane electrical con-
ductivity. The technique agrees well with measured urea
clearance [15]. We therefore undertook this study to
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evaluate the relationship between total dialysis dose,
taken as the product of measured Kecn and t, and death
risk. We also evaluated convenient body size measures
that might be used to assist prescription of Kt.
METHODS
The patient sample was taken from the clinical files
of Fresenius Medical Care (NA) (FMCNA). The pri-
mary analysis included 17,035 patients treated three times
weekly for whom demographic and outcome data, height
and weight measurements, and one or more treatments
measuring average Kecn and t during April 2002. Sur-
vival analyses included 15,570 patients treated three times
weekly treatment documented by actual treatments re-
ceived during the month. All values measured for each
patient during the month of April 2002 were averaged for
that patient. As such, the values represent characteristic
patient values and not individual measurements. Demo-
graphic and case mix measures like age were taken as of
April 30, 2002. The clinical observation period extended
for 1 year following that date.
The technology for measuring Kecn is incorporated
into the 2008H and 2008K dialysis hardware systems man-
ufactured by the Medical Products Division of FMCNA
and is based on measurement of an ionic dialysance [13].
Those values are averaged during the treatment to give an
average Kecn × t product (Kt) [11]. The ionic dialysance
so measured closely approximates the urea dialysance
(r = 0.98; urea = −2.0 + 1.01 × ionic) [15]. Thus, ionic
dialysance is an excellent proxy for the average urea clear-
ance during dialysis because clearance and dialysance are
equal quantities when the dialysate inlet concentration
of a substance equals zero [16] as it does for urea during
conventional single pass dialysate flow. Furthermore, the
Kecn and Kt value are easily measured with each and ev-
ery treatment and are readily available during and after
the treatment.
Primary analysis
The purpose of these analyses was to evaluate the as-
sociations of total treatment dose (Kecn × t) measured
by the on-line clearance method and body size (BSA)
with death risk. The primary outcome target was patient
survival evaluated as a function of dialysis dose and body
size measures in Cox models [17] using Proc Phreg of the
SAS statistical system. Models were evaluated without
and with adjustment for certain case mix measures that
included age, gender, race (black, white, and other), dia-
betic status (no or yes), and vintage on dialysis (<1/2 year,
1/2 to 1 year, 1 to 2 years, and ≥2 years). The equation of
DuBois and DuBois [18] was used to estimate BSA. The
BMI was calculated using the equation of Que´tlet [19].
Table 1. Characteristics of the patient population
Mean
or % SD 75th 50th 25th
Demographic data
Age years 61.1 15.0 73.0 63.0 51.0
Gender % male 53.0
Race
% white 45.4
% black 44.0
% other/miscellaneous 10.6
Diabetes % yes 48.4
Vintage months 40.5 44.0 53.2 27.2 11.9
Body size
Post dialysis weight kg 76.1 20.3 86.9 73.0 62.1
Body surface area m2 1.85 0.25 2.00 1.83 1.67
Body mass index kg/m2 27.1 7.4 30.4 25.7 22.2
Dialysis dose
Kecn mL/min 225.1 37.2 248.0 227.5 203.5
t min 217.47 28.1 238.8 215.8 199.1
Kecn × t L/Rx 49.0 10.5 55.4 48.6 42.1
Single-port Kt/V 1.55 0.27 1.71 1.54 1.38
Effective eKt/V 1.35 0.24 1.48 1.33 1.20
Frequency
(% 3 Rx/wk) 91.40
(% <3 Rx/wk) 5.54
(% >3 Rx/wk) 0.52
(% Not determinable) 2.54
Kecn is 1 to 22 determinations during April with 87.6% between 3 and 13
determinations inclusive.
Supplementary analyses
We also performed a supplementary analysis to com-
pare the shape of a risk profile for Kt indexed to BSA
(Kt/BSA) to similar profiles of Kt indexed to V as
Kt/V determined from urea kinetic methods. FMCNA-
affiliated clinics routinely determine and follow as clinical
quality measures a single-pool Kt/V (spKt/V) estimated
by a formal, iterative 2-point kinetic method and an effec-
tive Kt/V (eKt/V) estimated by transforming spKt/V us-
ing a standard equation [7]. Values for spKt/V and eKt/V
taken during February through April, 2002 were ex-
tracted from FMCNA clinical files and averaged for each
patient. The distributions of spKt/V and eKt/V values
were clipped at the 1st and 99th percentiles to eliminate
extreme outlying values. Survival time was then evalu-
ated as a function of either spKt/V or eKt/V using the
Cox method [17] as described earlier.
RESULTS
Table 1 describes demographic, body size, and dialy-
sis dose attributes of the patient population. The median
postdialysis weight, BSA, and BMI were 73.0 kg, 1.83 m2,
and 27.7 kg/m2, respectively. The median Kecn, t, and Kt
were 227.5 mL/min, 3.6 hours, and 48.6 L/treatment. The
median spKt/V and eKt/V were 1.54 and 1.33, respec-
tively.
Primary analysis
Figure 1 illustrates the forms of the relationships be-
tween the body size measures and the log-hazard for
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Fig. 1. Relationships between log-hazard for
death and deciles for the body size measures.
Abscissa values are the median for each body
size category.
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Fig. 2. Relationships between log-hazard for
death and deciles of the dialysis dose mea-
sures. Abscissa values are the median for each
dose category.
death; the linear R2 statistic for each relationship is also
shown. The relationship between log-hazard and BSA
was most nearly linear followed by body weight; the BMI
relationship appeared to contain a noticeable flattening at
its mid-range. BSA therefore was chosen as the primary
body size measure for further analysis. Figure 2 illustrates
similar relationships for the dialysis dose measures. All
suggested improving hazard with increasing dose.
Table 2 summarizes the results of those survival anal-
yses in which all dose and size measures were treated
as continuous. The hazard ratios less than 1.0 indicate
that increasing values of each were associated decreasing
death risk in single-variable models whether case mix ad-
justed or not. Including all three primary measures in a
single model (Table 2, part 2) led to the extinction of t as
a significant associate of death risk, but increasing values
of both Kecn and BSA were associated with lower risk.
Kecn and t were weakly but significantly and directly cor-
related (r = 0.028; P < 0.001) suggesting that clinicians
tended to prescribe longer t with higher Kecn. That incli-
nation appeared marginal however.
Increasing values of both the Kt product and BSA were
associated with lower death risk in both unadjusted and
adjusted models (Table 2, part 3). An interaction term
added to those models was positive [hazard ratio (HR) >
1.0], suggesting that the deterioration of death risk with
decreasing Kt was worse at lower than higher BSA, but
was significant only in the case mix adjusted model. In
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Table 2. Summary of dialysis treatment and body size statistical models for patients treated three times weekly
Models Parameters Adjustments Chi Square P value HR 95% Cl
Part 1 Kecn U 82.6 <0.001 0.995 0.994–0.996
CM 48.5 <0.001 0.996 0.994–0.997
Single t U 21.4 <0.001 0.996 0.995–0.998
Measures CM 4.7 =0.030 0.998 0.996–1.000
U 105.8 <0.001 0.407 0.343–0.483
BSA CM 65.4 <0.001 0.410 0.331–0.509
Part 2 Kecn 47.3 <0.001 0.996 0.995–0.997
t U 0.1 NS 1.000 0.998–1.001
Combined Models BSA 52.6 <0.001 0.457 0.389–0.581
Kecn 31.1 <0.001 0.996 0.995–0.998
t CM 0.0 NS 1.000 0.998–1.002
BSA 42.6 <0.001 0.457 0.361–0.578
Part 3 Kt U 29.5 <0.001 0.987 0.982–0.991
BSA 41.8 <0.001 0.527 0.434–0.640
Kt and BSA Kt CM 17.6 <0.001 0.989 0.984–0.994
BSA 36.2 <0.001 0.491 0.390–0.619
Kt 3.5 =0.062 0.974 0.947–1.001
BSA U 6.8 =0.009 0.375 0.180–0.784
Kt × BSA 0.9 NS 1.007 0.990–1.022
Kt 9.3 =0.002 0.955 0.927–0.984
BSA CM 15.9 <0.001 0.199 0.090–0.440
Kt × BSA 5.5 =0.019 1.019 1.003–1.035
Abbreviations are: u, unadjusted, cm, case mix adjusted; NS, P > 0.10; HR, hazard ratio; 95% Cl, 95% confidence interval for the hazard ratio.
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Fig. 3. Surface plot illustrating the relationship between the hazard
ratio for death and combined Kt and body surface area (BSA) in the case
mix adjusted model treating all measures as continuous. Bars describe
the surface to facilitate reading of its form. The Kt and BSA axes are
based on the 1st and 99th percentile values of the measures.
other words, the adverse effect of lowering Kt appeared
relatively greater in small than large patients.
Figure 3 is a surface plot illustrating the form of the
relationship. The deterioration of hazard is quite steep
at the lowest BSA, increasing by a factor of 19.8 times
(HR at BSA 1.2 m2 deteriorated from 0.6 at Kt = 65.0 L/
treatment to 11.9 at Kt = 25.0 L/treatment) but is less
steep at the highest BSA deteriorating by a factor of only
7.5 times (HR at BSA 2.2 m2 deteriorated from 0.2 at
Kt = 65.0 L/treatment to 1.5 at Kt = 25.0 L/treatment).
In other words, the benefit of increasing dose is relatively
less dramatic in larger patients.
Figure 4 illustrates the relationship in a cross categoric
analysis in which patients were classified into 25 groups
according to their combined values for Kt and BSA. The
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Fig. 4. The hazard ratio for death among patients grouped their com-
bined values of Kt and body surface area (BSA).
range of values available for evaluation is much smaller
than possible with continuous measure analysis like that
illustrated by Figure 3. None of these analyses, however,
suggest that higher Kt is required in linear proportion to
increasing body size when deciding adequate treatment.
To the contrary, they suggest that if anything smaller pa-
tients require relatively more Kt than larger patients to
achieve comparable levels of mortal risk.
Dialysis dose indexed to BSA and the kinetic Kt/V
This supplementary analysis suggested that the ratio
Kt/BSA was significantly and favorably associated with
death risk (HR = 0.986; 95% CI = 0.977 to 0.944; P <
0.001) when evaluated as a continuous measure. Com-
parable statistics for the spKt/V and eKt/V were HR =
0.925 (95% CI = 0.795 to 1.075; P = NS) and HR = 0.862
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Fig. 5. Comparison of risk profiles for
Kt/body surface area (BSA), single-pool Kt/V
(spKt/V), and effective Kt/V (eKt/V) shown
as relationships between log-hazard for death
and deciles for the measures. Abscissa values
are the median for each category.
(95% CI = 0.721 to 1.030; P = 0.103), respectively. The
risk profiles for the three ratios are shown in Figure 5
and can be compared to similar profiles for the body size
and dialysis dose measures shown in Figures 1 and 2. The
profiles shown in Figure 5 all suggest a nonlinear and ir-
regular form that is nearly flat but in which risk at both
low and high ends of the distributions are greater than at
the low points in their middles.
DISCUSSION
The purpose of this project was to evaluate the associ-
ation of delivered dialysis dose estimated from the online
measurement of small molecule clearance, Kecn, and the
length of the treatment, t, with death risk. Simple body
size measures that are easily calculated and might be used
to evaluate total dose per treatment (Kt) were also eval-
uated.
The BSA is a familiar, convenient and reliable proxy
for body size. BSA is also strongly associated with death
risk in roughly log-linear fashion demonstrated here and
elsewhere [20]. BSA was therefore selected as the pri-
mary body size proxy for use in statistical models evalu-
ating both size and dialysis dose. Body weight might also
be reliably used but was not evaluated here. Similarly,
estimates of V or TBW might be used but were not eval-
uated in this study.
Combining Kecn, t, and BSA in statistical models led
to the extinction of t as a significant death risk predictor.
See Table 2, part 2 models. Thus, these data suggest that
increasing clearance is as effective as increasing time if
a clinician wants to increase Kt. Dialysis time, however,
cannot be ignored when considering total dialysis dose.
First, the range of time reported here was relatively nar-
row; one half of patients were treated at time between
3 hours, 20 minutes, and 4 hours, 0 minutes; 90% were
treated between 2 hours, 56 minutes, and 4 hours, 18 min-
utes. Thus, very long and very short treatment lengths
were not well represented in these data and the findings
with respect to time may have been otherwise if they were.
Furthermore, the NCDS evaluated dialysis time and
small molecule (urea) directed therapy separately in a
2 by 2 factorial model [4]. It found that inadequate
small molecule removal led to substantially greater mor-
bid risk if those removal rates were low (P < 0.0001).
The study was stopped early for patient safety reasons
given that finding. Only 151 patients had been random-
ized into the four treatment groups. The probability of
greater morbidity (as estimated by survival time to death
or first hospitalization) associated with short time treat-
ment (2.5 to 3.5 hours, average = 3.25 hours) compared
to longer time treatment (4.5 to 5.0 hours; average =
4.5 hours) approached statistical significance (P = 0.06)
when the study was stopped [4]. One cannot reasonably
conclude from those data that short dialysis was not as-
sociated with greater morbidity given the early stopping
of the study and the small number of patients random-
ized. To the contrary, prudence dictates the conclusion
that short treatment may well have been associated with
greater morbidity given that the morbidity rate differ-
ence approached statistical significance and the study was
stopped early with so few patient participants. Argued
simply, the NCDS was not adequately powered to declare
as statistically significant the difference between treat-
ment time arms because it was stopped early for other
reasons. The null hypothesis (no difference between
times) was then not rejected according to usual criteria
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(P < 0.05) even though it may have been true in fact thus
leading to a type II statistical error.
About 95% of patients reported here were treated for
times less than the average of long NCDS treatment.
Such short dialysis has been a common practice in the
United States. The average treatment time in the stan-
dard and high dose arms of the HEMO Study [5], for
example, were only 3.2 and 3.6 hours. Average treatment
time was 3.6 hours at year-end 2002, up from 3.3 hours
in1993, according to a recent national survey [21]. Thus,
the treatment times reported here were longer than the
short time arm of the NDCS and the standard dose arm
of the HEMO Study. They are comparable to the recent
national survey [21] and the high dose arm of the HEMO
Study. All of those times were more than one and one
fourth hours (25%) shorter than the long time arm of the
NCDS. It is possible, therefore, that treatment time may
have not have been extinguished as a significant risk pre-
dictor in these analyses if substantial numbers of patients
had been treated at times in the range of 41/2 to 5 hours or
more. We should note, however, that dialysis membranes
used today have more open structures than those used in
the NCDS. The clearances of molecules larger than urea
is therefore proportionately greater at any given treat-
ment time so the studies may not be strictly comparable
with respect to treatment time.
Finally, if dialysis treatment were sufficiently short, ap-
proaching 0 minutes, for example, no treatment would
be delivered no matter the dialyzer clearance. Therefore,
time must be included when treatment is prescribed and
cannot be ignored.
Kt and BSA were both associated with mortal risk; in-
creasing values of each were associated with lower risk
supporting previous findings [20]. An interaction term
between Kt and BSA was positive, and therefore asso-
ciated with a hazard ratio greater than 1.00, in both the
unadjusted and the case mix adjusted models but was
significant only in the latter. Such findings suggest that
proportionally higher Kt is required for smaller persons.
The findings are similar to those reported earlier that
used transformations of kinetic data instead of direct
measurements to estimate Kt [20]. Both those data and
these suggest if anything that smaller patients require
proportionately greater total dialysis dose than larger pa-
tients. The deterioration of mortal risk with decreasing Kt
for smaller patients (by a factor approaching 20 times in
this study) is greater than for larger patients (7.5 times).
The previous report [20] suggested similar death risk de-
terioration in both low and high BSA patients (16.7 times
and 7.7 times, respectively). Thus, analyses that used
two different methods to estimate Kt produced compa-
rable results. These statistical patterns seem to confirm
the judgments of clinicians who treat smaller patients at
higher URR, and therefore Kt/V, than larger patients ac-
cording to a national survey [22].
Indexing Kt to BSA, giving a Kt/BSA ratio, led to
curves in which death risk was greater at the extremes
of the Kt/BSA distribution than at lower points in their
middle regions. The shape of the profile was similar to
profiles for spKt/V and eKt/V estimated using formal
urea kinetic methods. The lack of significant association
between survival time and either spKt/V or eKt/V when
they are evaluated as continuous measures likely evolved
from the nonlinear relationship between both ratios and
death risk suggested by Figure 5. Those findings are not
unlike the U or reversed J-shaped risk profiles that have
been reported when the urea reduction ratio is used to
describe dialysis dose [23]. Death risk profiles evaluat-
ing the URR, spKt/V, and eKt/V tend to be U-shaped or
reversed J-shaped while such profiles evaluating Kt are
not [24]. The reasons for the pattern have been discussed
previously [3] and likely follow in part from dividing one
measure favorably associated with survival (Kt) by an-
other (V or BSA) [25].
One is left then with the question of prescribing dial-
ysis dose, Kt, in terms of body size. These data do not
address that issue directly. Current tradition suggests in-
dexing Kt to V as a simple ratio [1]. V has generally been
assumed to equal TBW. TBW can be estimated by sev-
eral anthropometric methods [32] using the height and
weight of patients, as is done when calculating a BSA
[18]. Recent studies, however, suggest that V may be less
than TBW in dialysis patients with chronic renal failure
[26] but larger than TBW in dialysis patients with acute
renal failure [27, 28]. Thus, a kinetic-based estimate of
V may be desirable. Such an estimate can be performed
periodically using formal, iterative urea kinetic methods
to estimate a single-pool V (spV) and then adjusting the
estimate to an effective or double-pool V (eV) [29] as
done elsewhere [26, 27]. By alternative, an spKt/V can be
estimated using standard equations [6] as is commonly
done [1] and dividing the resulting value into measured
(Kecn × t) to estimate an spV. The spKt/V can be con-
verted to an eKt/V using one of several equations [7, 30].
The resulting eKt/V can then be divided into measured
(Kecn × t) to estimate a double pool V, eV. Periodic es-
timates of spV and/or eV can then be used as indexing
values for measured Kt to monitor a Kt/V with each and
every treatment.
Such a procedure, however, contemplates a fixed Kt/V
target value for all patients large and small. These data
confirm earlier observations [20] suggesting that the
assumption may be incorrect confirming a conclusion
seemingly embraced by practicing clinicians [22]. Curve-
splitting techniques [31] suggested that Kt values, esti-
mated from measurements of pre- and postdialysis BUN
concentration [20], suggested a possible relationship
between death risk, Kt, and V (estimated by the Cher-
tow method [32]), that required a minimum Kt thresh-
old dose. The relationship appeared linear and was
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Kt = 30 + 1/2 Chertow V [unpublished observations,
Lowrie, EG: Letter to the editor Kidney Int 63:1962,
2003]. Thus, a patient with V = 30 L would be treated
at Kt = 45 L/treatment (Kt/V = 1.5) while a patient with
V = 50 liters would be treated at Kt = 55 L/treatment
(Kt/V = 1.1). Studies are now in progress to confirm or
revise those preliminary findings base on the direct mea-
surement of Kecn and t using the on-line method.
Recent statistics [33] from the HEMO Study [5] tend
to support the theory that smaller persons require pro-
portionately higher Kt per unit of V, which is to say
higher Kt/V, for adequate treatment than larger persons.
Women in the standard dose arm of the HEMO Study
had marginally worse (P = 0.02) survival than women
in the high dose arm; there was no difference between
the arms for men. Women (average V = 31.3 L) in the
standard dose arm were treated at comparable Kt/V to
larger men (V = 39.6). Women, however, were treated
at much lower Kt (38.2 L/treatment) than men (45.5).
Thus smaller persons (women) appeared to require pro-
portionately higher Kt/V than larger persons (men) in the
HEMO Study [33] as they appear to here and elsewhere
[20]. The reason for the apparent need for higher Kt/V
in smaller persons may evolve simply from failure to ac-
count for a possible nonzero intercept requirement in the
relationship between necessary Kt and V when evaluat-
ing dialysis dose as suggested earlier in this discussion.
A brief description of the principles and methods of
determining Kecn may be in order even though a de-
tailed discussion is beyond the scope of these data and
this project. The technology rests on the assumption that
ionic transfer across a dialysis membrane is similar to urea
mass transfer and that differences of ionic concentration
can be detected by conductivity measurement probes. It
is embodied in, and available commercially from, for two
companies (Gambro AB, Stockholm, Sweden, and Fre-
senius Meidical Care AG, Bad Homburg, Germany), the
details of which are part of their confidential intellec-
tual property. In general, however, the conductivity at the
dialysate outlet of an artificial kidney depends on the con-
ductivity at the inlet and the ionic mass transfer across the
membrane. Mass transfer depends on plasma water ion
content and ionic dialysance. If the dialysate inlet con-
centration is changed briefly by an injection of sodium
chloride or dilution of dialysate, for example, the outlet
concentration will change. Knowing the outlet concentra-
tion at two such changed inlet concentrations permits the
calculation of ionic dialysance assuming no or minimal
change of blood water inlet conductivity [13, 34]. Ionic
dialysance can then be measured multiple times during
the course of a dialysis treatment and values averaged
during and after treatment. Ionic dialysance closely ap-
proximates urea dialysance for both commercial systems
[11–15, 34–36]. Urea dialysance equals urea clearance in
single pass systems like those used for clinical dialysis [16]
Thus, a good estimate of small molecule Kt can be conve-
niently determined as a running average during and as a
final value after treatment. Technologies other than ionic
dialysance could be used to support similar capabilities
[37].
Finally, these data, like much in the clinical literature,
evaluate dialysis dose in terms of small molecule markers,
like urea, that behave in particular pharmacokinetic ways
[2]. However, the concentrations of other solutes like
potassium, phosphorus, and bicarbonate have all been as-
sociated with death risk among dialysis patients [38, 39]
and likely deserve similar attention. Another purpose of
dialysis treatment is the removal of excess body water
that accumulates between treatments. Inadequate or ex-
cessive rates of water removal can also lead to excess mor-
bidity and mortality among patients [40]. Thus, strategies
for removing body water during dialysis treatment also
deserve substantial attention and research.
CONCLUSION
These data demonstrate the practical feasibility of de-
termining the total dose of dialysis treatment from on-line
measurements during each treatment. The relevance of
those measures to a clinical outcome like mortal risk is
also demonstrated. As such, this strategy may be consid-
ered in addition traditional urea kinetic methods to guide
and monitor hemodialysis therapy.
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